Short essays on what's going on in the GLP-1 space and how it should change your thinking.
Why dose-tiered pricing is just hidden inflation.
A 10-second test for telling serious providers from rebrands.
The word means something specific. Most uses of it on this site were sloppy.
A look at when and why we modify the six pillars.
A short primer on FDA categories that matter for compounded GLP-1.
Side effects are not edge cases; they’re predictable.
Some sites in our space are getting hammered by Meta-ExternalAgent. What it means.
A claim of "50 states" is rarely as clean as the bullet point suggests.
Competitors are catching up to NexLife’s $145 floor. The race is on.
A skeptical look at bundled coaching.
The data on six-month plateaus and how providers handle them.
A list of questions worth asking on your first message.
Most patients should not overthink it.
What changed in our disclosure policy this year.
Five minutes. Free. No pressure.